Adma Biologics (ADMA) FY2020 results: revenue $42 million, up 43.9% on the year
Adma Biologics, Inc. (ADMA) reported revenue of $42 million for fiscal 2020, the year ended 31 December 2020, up 43.9% on the year before. Net income was -$76 million, and diluted earnings per share $-0.88. The figures are the company's own, from the 10-K it filed with the SEC on 25 March 2021.
Revenue
$42 million
+43.9% on the year
FY2013FY2020
Operating margin
-153.8%
-141.1% a year earlier
FY2013FY2020
Net income
-$76 million
FY2013FY2020
Diluted EPS
-$0.88
FY2013FY2020
this yearthe year beforeHover a bar for its figure.
The year in brief
Income statement (profit and loss)
$ million
FY2020
FY2019
FY2018
On the year
Last 8 years
Revenue
42.2
29.3
17.0
+43.9%
Cost of revenue
61.3
39.5
42.2
+55.2%
Gross profit
-19.1
-10.2
-25.2
Gross margin
-45.2%
-34.6%
-148.4%
Research and development
5.9
2.3
3.9
+152.0%
Selling, general and administrative
35.1
n/a
n/a
Operating income
-64.9
-41.4
-60.3
Operating margin
-153.8%
-141.1%
-354.9%
Interest expense
12.0
9.0
5.5
+33.3%
Income tax
0.0
0.0
0.0
Net income
-75.7
-48.3
-65.7
Net margin
-179.4%
-164.5%
-387.1%
Diluted EPS
-$0.88
-$0.89
-$1.45
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
FY2020
FY2019
FY2018
On the year
Last 8 years
Operating cash flow
-102
-76.2
-62.7
Capital expenditure
12.7
3.8
2.1
+233.9%
Free cash flow
-115
-80.0
-64.8
Free cash flow margin
-271.7%
-272.6%
-381.4%
Cash from investing
-12.7
-3.8
-2.1
Cash from financing
144
80.0
42.9
+79.9%
Depreciation and amortisation
3.2
2.4
2.6
+33.3%
Share-based compensation
2.9
2.7
2.2
+7.7%
Diluted shares, weighted
86m
n/a
n/a
Shares outstanding at period end
105m
59m
46m
+76.8%
Balance sheet
$ million
FY2020
FY2019
FY2018
On the year
Last 8 years
Shareholders' equity
88.2
26.2
19.8
+236.9%
Debt
93.0
83.2
44.1
+11.7%
Operating lease liabilities
4.3
n/a
n/a
Other liabilities
22.1
17.7
25.0
+25.0%
Total liabilities and equity
208
127
88.9
+63.4%
Fixed assets
41.6
31.7
30.1
+31.0%
Goodwill
3.5
3.5
3.5
0.0%
Intangible assets
2.4
3.2
4.0
-22.6%
Cash and equivalents
55.9
26.8
26.8
+109.0%
Receivables
13.2
3.5
1.4
+281.5%
Inventory
81.5
53.1
18.6
+53.7%
Other assets
9.4
5.4
4.5
+75.2%
Total assets
208
127
88.9
+63.4%
10-K for the year ended 31 December 2020, filed 25 March 2021: the filing.